Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANSOLYSEN vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pentolinium (ANSOLYSEN) is a ganglionic blocking agent that competitively antagonizes nicotinic acetylcholine receptors at autonomic ganglia, blocking both sympathetic and parasympathetic transmission.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Severe hypertension,Hypertensive crisis
Hypertension
Initial: 2.5 mg intramuscularly or subcutaneously every 6 hours, gradually increased to 5-20 mg every 6 hours as needed.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may be prolonged to 24-48 hours in renal impairment, necessitating dose adjustment.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Hepatic metabolism; excreted primarily unchanged in urine.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal excretion predominates (approximately 70-80% as unchanged drug via glomerular filtration; remainder as metabolites). Biliary/fecal elimination accounts for <10%.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Approximately 30-40% bound to serum albumin; binding is reversible and concentration-independent.
~90%, primarily to albumin
Vd is 0.5-1.0 L/kg indicating extensive tissue distribution (primarily in highly perfused organs), with little accumulation in fat.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral bioavailability is low (10-25%) due to significant first-pass metabolism; subcutaneous bioavailability >90%; intramuscular near 90%; intravenous 100%.
Oral: 50–60% (extensive first-pass metabolism)
Contraindicated in severe renal impairment. For GFR 10-50 m L/min: reduce dose by 50% and increase dosing interval. For GFR <10 m L/min: avoid use.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
No specific guidelines; use with caution in severe hepatic impairment due to potential for increased toxicity.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not established; safety and efficacy in children have not been determined.
Not recommended for pediatric use; safety in children under 12 years not established.
Use with caution; start at lower end of dosing range due to increased sensitivity and risk of hypotension and falls.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None specified in standard references.
None
Severe hypotension,Paralytic ileus,Bladder atony,Pupillary dilatation and photophobia,Loss of accommodation,Syncope and precipitating angina,Interstitial pulmonary edema and fibrosis
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to pentolinium,Uncooperative patients,Coronary insufficiency,Recent myocardial infarction,Severe renal impairment,Pyloric stenosis,Glaucoma,Bladder neck obstruction,Prostatic hypertrophy
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid tyramine-rich foods (aged cheese, cured meats, fermented products) as ganglionic blockers may potentiate pressor responses. Limit salt intake to manage blood pressure. Grapefruit juice may alter drug metabolism? No known significant interaction; however, general caution with high-tyramine foods is advised.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
First trimester: Potential for teratogenic effects based on animal studies; human data limited. Second and third trimesters: Risk of fetal bradycardia, hypothermia, and respiratory depression due to ganglionic blockade. May cause neonatal hypotension if used near term.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Excretion in human milk unknown; M/P ratio not available. Due to potential for adverse effects in nursing infants (e.g., hypotension, gastrointestinal disturbances), caution advised; consider alternative therapy.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
No specific dosing guidelines; monitor maternal response carefully. Increased volume of distribution may require higher doses, but increased sensitivity may necessitate dose reduction. Use lowest effective dose.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
ANSOLYSEN (mecamylamine) is a secondary amine and a ganglionic blocker used in severe hypertension. Due to its narrow therapeutic index and risk of paralytic ileus, it is rarely used today. Monitor for orthostatic hypotension, urinary retention, and constipation. Avoid in patients with pyloric stenosis, recent myocardial infarction, or glaucoma. Use with caution in renal impairment as drug is renally excreted.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take exactly as prescribed; do not double doses if missed.,Rise slowly from lying or sitting to prevent dizziness.,Avoid alcohol and hot baths/saunas as they may worsen hypotension.,Report severe constipation, difficulty urinating, or blurred vision immediately.,Do not discontinue abruptly; taper under medical supervision.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANSOLYSEN vs ALDORIL 15, answered by our medical review team.
ANSOLYSEN is a Antihypertensive that works by Pentolinium (ANSOLYSEN) is a ganglionic blocking agent that competitively antagonizes nicotinic acetylcholine receptors at autonomic ganglia, blocking both sympathetic and parasympathetic transmission.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANSOLYSEN and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANSOLYSEN is: Initial: 2.5 mg intramuscularly or subcutaneously every 6 hours, gradually increased to 5-20 mg every 6 hours as needed.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANSOLYSEN and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANSOLYSEN is classified as Category C. First trimester: Potential for teratogenic effects based on animal studies; human data limited. Second and third trimesters: Risk of fetal bradycardia, hypothermia, and respiratory. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.